A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.
The DOI matches its Crossref record.
Abstract
2528^ Background: LEE011, an orally bioavailable, highly specific CDK4/6 inhibitor, causes cell cycle arrest and tumor growth inhibition in multiple preclinical models with intact retinoblastoma protein (pRb+). Methods: Pts withpRb+ advanced solid tumors and lymphomas were treated with escalating doses of LEE011 on a 21-of-28-d or continuous schedule. Dose escalation was guided by a Bayesian Logistic Regression Model with overdose control principle. Primary objective: to establish the MTD and/or RP2D of LEE011. Secondary objectives: safety, efficacy, PK, and PD. Results: As of Jan 17, 2014, 132 pts were treated; 85 during escalation (50–1200 mg/d) and 47 during RP2D expansion. The following results are from dose escalation (data cut-off: July 2, 2013). Ten DLTs were observed in 10 pts: neutropenia (3 pts); asymptomatic thrombocytopenia (2 pts); mucositis, pulmonary embolism, hyponatremia, QTcF prolongation (>500 ms), and increased creatinine (1 pt each). The MTD and RP2D were declared as 900 and 600 mg/d on 21-of-28-d schedules, respectively. The most common study drug-related AEs (all grades) were neutropenia (40%), leukopenia (36%), nausea (35%), and fatigue (27%). G3/4 AEs included neutropenia (19%), lymphopenia (14%), and leukopenia (12%). Asymptomatic QTcF prolongation (>450 ms) was seen at doses ≥600 mg/d: in 10% of pts at 600 mg/d and in 27% of pts at doses >600 mg/d. Plasma exposure increases were slightly higher than dose proportional; mean T1/2 at RP2D was 36.2 h. Paired skin biopsies from 40 pts showed reductions of ≥50% from baseline in Ki67 and phospho-pRb in 55% and 42% of samples, respectively. Among 70 evaluable pts, 2 (2.9%; 600 mg/d) had confirmed PRs: 1 pt with PIK3CA-mut, CCND1-amp, ER+ breast cancer; 1 pt with BRAF/NRAS-WT, CCND1-amp melanoma. SD for ≥4 and ≥6 cycles was seen in 26% and 14% of pts, respectively. Conclusions: LEE011 showed an acceptable safety profile, dose dependent plasma exposure, evidence of target inhibition and preliminary signs of clinical activity. The study expansion is confirming safety and efficacy. Further studies are investigating LEE011 as a single agent (neuroblastoma and malignant rhabdoid tumors) and in combination with other agents (breast cancer and melanoma). Clinical trial information: NCT01237236.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
“7 hr (69, 70) Tmax 4 hr t1/2 24–36 hr (90, 91) Tmax 4–6 h t1/2 17–38 h (crosses blood:brain barrier; refs.”
Self-citationHerrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Metadata
- Authors
- Infante, J. R., Shapiro, G., Witteveen, P., Gerecitano, J. F., Ribrag, V., Chugh, R., Issa, I., Chakraborty, A., Matano, A., Zhao, X., Parasuraman, S., & Cassier, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-05-20
- Volume
- 32
- Issue
- 15_suppl
- Pages
- 2528-2528
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1863237805
- Cited by
- 61
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.2528
- The paper
- Infante, J. R., Shapiro, G., Witteveen, P., Gerecitano, J. F., Ribrag, V., Chugh, R., Issa, I., Chakraborty, A., Matano, A., Zhao, X., Parasuraman, S., & Cassier, P. (2014). A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.2528
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.